Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 611 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Recurrent NSCLC Clear all

Conditions: Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Interventions: SMS001; Drug
Lead sponsor: ToLymph Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer
Interventions: computed tomography, positron emission tomography, fludeoxyglucose F 18; Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Cancer
Interventions: Ibrutinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Clinical Observation, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Standard Follow-Up Care, Therapeutic Conventional Surgery; Other · Radiation · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 2
States / cities: Denver, Colorado • Houston, Texas

Conditions: Anorexia, Cachexia, Fatigue, Lung Cancer
Interventions: infliximab, docetaxel, placebo; Biological · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 188
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more

Conditions: Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local
Interventions: Avastin (bevacizumab), Tarceva (erlotinib HCl); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 48
States / cities: Bakersfield, California • Concord, California • Fullerton, California + 40 more

Conditions: Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Carboplatin, Computed Tomography, Intensity-Modulated Radiation Therapy, Paclitaxel, Positron Emission Tomography, Proton Beam Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Cancer
Interventions: recombinant adenovirus-hIFN-beta; Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer, Prostate Cancer
Interventions: radiation therapy, stereotactic radiosurgery; Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Modesto, California + 50 more

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Pemigatinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Los Angeles, California • Fort Myers, Florida • Miami, Florida + 4 more

Conditions: Lung Cancer
Interventions: Gleevec and Taxotere; Drug
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Kansas City, Kansas • Kansas City, Missouri

Conditions: Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
Interventions: entinostat, Erlotinib, Exemestane; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma, Lung Neoplasms
Interventions: Drug: Hyperacute Lung Cancer Cell Vaccine; Biological
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: gemcitabine hydrochloride, tacedinaline; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 9
States / cities: Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 6 more

Conditions: Advanced Lung Carcinoma, ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Brigatinib, Local Consolidation Therapy; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: erlotinib hydrochloride, celecoxib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent
Interventions: Nivolumab, nab-paclitaxel; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Edgewood, Kentucky • Saint Louis Park, Minnesota • St Louis, Missouri + 1 more

Conditions: Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging; Drug · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: NSCLC, HNSCC
Interventions: eftilagimod alpha, pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Immutep S.A.S.; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Huston, Texas

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Dexamethasone, Device for PET, Laboratory Biomarker Analysis, Positron Emission Tomography; Drug · Device · Other + 1 more
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Gefitinib, Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 35
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 32 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy; Procedure · Drug · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 79
States / cities: Tucson, Arizona • Corona, California • Duarte, California + 63 more

Conditions: Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
Interventions: BMF-219; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Goodyear, Arizona • Encinitas, California • La Jolla, California + 15 more

Conditions: Lung Cancer
Interventions: docetaxel, vinorelbine tartrate; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 96
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Search by objective public record fields.

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Vaccine Treatment for Advanced Non-Small Cell Lung Cancer

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

Iressa Versus Docetaxel (Taxotere)

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer